Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.43 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8637389 | 0.91 | PTGS2 (0.53) | PTGESPTGS2PTGS1TRPC3CYP2C9 | |
| SCHEMBL8639293 | 0.90 | PTGS2 (0.54) | PTGESPTGS2PTGS1PDPK1FFAR4 | |
| SCHEMBL8639807 | 0.89 | PTGS2 (0.43) | PTGESPTGS2PTGS1TRPC3CYP2C9 | |
| SCHEMBL8644138 | 0.87 | PTGS2 (0.42) | PTGESPTGS2PTGS1TRPC3CYP2C9 | |
| SCHEMBL7135445 | 0.85 | PTGS2 (0.51) | PTGESPTGS2PTGS1TRPC3CYP2C9 | |
| SCHEMBL8643950 | 0.83 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL8641600 | 0.83 | PTGS2 (0.44) | PTGESPTGS2PTGS1CYP2C9ALOX5 | |
| SCHEMBL8638531 | 0.83 | PTGS2 (0.54) | PTGS2PTGS1PDPK1 | |
| SCHEMBL27967579 | 0.82 | PDPK1 (0.45) | PTGESPTGS2PTGS1TRPC3CYP2C9 | |
| SCHEMBL8640002 | 0.82 | PTGS2 (0.42) | PTGS2PTGS1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | Neonc Technologies, Inc. (US) | 2021-10-19 | — | — | US | claimed |
| US-9499461-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2016-11-22 | — | — | US | claimed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | claimed |
| EP-4323070-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | disclosed |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4034567-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-02-24 | — | — | US | disclosed |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | Neonc Technologies, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3612185-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | Neonc Technologies, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2019-06-06 | — | — | US | disclosed |
| WO-2019014420-A1 | COMPOSITIONS AND METHODS OF DECREASING MEDICATION ERRORS | AZHC, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2018195149-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | Neonc Technologies, Inc. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20170297985-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | NEONC TECH INC (US) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
| US-20170297985-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, REL, CHAT | PTGES 280/4885PTGS2 878/4885PTGS1 901/4885 |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | PTGES 199/4885PTGS2 754/4885PTGS1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.